Proinflammatory cytokines alter/reduce esophageal circular muscle contraction in experimental cat esophagitis

Weibiao Cao,1 Ling Cheng,1 José Behar,1 Claudio Fiocchi,2 Piero Biancani,1 and Karen M. Harnett1

1Department of Medicine, Rhode Island Hospital and Brown University, Providence, Rhode Island 02903; and 2Division of Gastroenterology, University of Cleveland, Case Western Reserve University, Cleveland, Ohio 44106

Submitted 12 May 2004 ; accepted in final form 9 July 2004


    ABSTRACT
 TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Cholinergic mechanisms are largely responsible for esophageal contraction in response to swallowing or to in vitro electrical field stimulation (EFS). After induction of experimental esophagitis by repeated acid perfusion, the responses to swallowing and to EFS were significantly reduced but contraction in response to ACh was not affected, suggesting that cholinergic mechanisms are damaged by acid perfusion but that myogenic mechanisms are not. Measurements of ACh release in response to EFS confirmed that release of ACh was reduced in esophagitis compared with normal controls. To examine factors contributing to this neuropathy, normal esophageal strips were incubated for 1–2 h with the proinflammatory cytokines IL-1{beta} (100 U/ml), IL-6 (1 ng/ml), or TNF-{alpha} (1 ng/ml). IL-1{beta} and IL-6 levels, measured by Western blot analysis, increased in esophagitis compared with normal circular muscle. IL-1{beta} and IL-6 reduced contraction in response to EFS (2–10 Hz, 0.2 ms) but did not affect ACh-induced contraction, suggesting that these cytokines inhibit ACh release without affecting myogenic contractile mechanisms. EFS-induced ACh release was significantly reduced in normal esophageal strips by incubation in IL-1{beta} or IL-6, suggesting that they may contribute to the contractility changes. TNF-{alpha} at 1 ng/ml, however, did not affect the response to ACh or to electrical stimulation but inhibited both at higher concentrations. TNF-{alpha} levels were low in normal muscle and did not increase with esophagitis. The data suggest that the proinflammatory cytokines IL-1{beta} and IL-6 contribute to reduced esophageal contraction by inhibiting release of ACh from myenteric neurons.

smooth muscle; signal transduction; hydrogen peroxide


CYTOKINES REPRESENT A COMPLEX group of secreted molecules involved in most aspects of inflammation in all organs and systems, including intestinal inflammation (46, 52). A number of properties are attributed to these proteins, which mediate stimulatory or inhibitory signals within one or multiple cell types. Cytokines are grouped according to common functional characteristics, and cytokines such as IL-1{beta}, TNF-{alpha}, and IL-6 are classified as proinflammatory because of their roles in inflammation-mediated tissue damage.

The bulk of information on cytokines in the gastrointestinal tract is based on studies of human inflammatory bowel disease (IBD), in which levels of proinflammatory cytokines are almost invariably elevated in the affected tissue. High concentrations of IL-1 (IL-1{alpha} and IL-1{beta}) are found in both Crohn's disease and ulcerative colitis intestine (38, 58), where its local effects are largely determined by the relative concentration of its natural receptor antagonist (IL-1ra). IL-6 is also consistently elevated in IBD mucosa derived primarily from macrophages and epithelial cells (34, 53). In contrast to IL-1 and IL-6, protein and mRNA levels of TNF-{alpha} have been reported as both normal and elevated in IBD. High TNF-{alpha} concentrations are found in the stools of children with Crohn's disease and ulcerative colitis (9), and production of TNF-{alpha} is high in cultures of ulcerative colitis mucosal mononuclear cells (47). In some but not in all studies, in situ hybridization reveals elevated TNF-{alpha} mRNA in macrophages infiltrating IBD tissues (11).

In addition to IBD, proinflammatory cytokines are also elevated in other gastrointestinal conditions characterized by chronic inflammatory processes of infectious or autoimmune etiology, such as Helicobacter pylori-induced gastritis and celiac disease (36, 43). However, very little is known about cytokine profiles in esophagitis. In a recent study, Fitzgerald et al. (21) found that, compared with noninflamed squamous esophageal epithelium, esophagitis tissue is characterized by significantly increased levels of IL-1{beta}. Others found that mucosal biopsies from children and adults with reflux esophagitis released higher amounts of IL-6 than normal esophageal mucosa (18, 48). More importantly, it is unknown whether circular muscle cells produce proinflammatory cytokines in esophagitis and what effect they may have on esophageal contractility.

In the present investigation, we examined IL-1{beta}, IL-6, and TNF-{alpha} as possible inflammatory mediators produced in experimental esophagitis in cats and compared motor disturbances induced by these cytokines to those observed in esophagitis specimens. The results show that IL-1{beta} and IL-6, but not TNF-{alpha}, are present in the muscle layer of esophagitis and that they induce some of the changes in motor function that occur with esophagitis. We conclude that IL-1{beta} and IL-6 may be responsible for some of the motor function changes observed in experimental esophagitis.


    METHODS
 TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Esophagitis model. Experimental procedures were approved by the Animal Welfare Committee of Rhode Island Hospital. Adult male cats weighing between 3.5 and 5.5 kg were used in this study. After an overnight fast, they were anesthetized with ketamine hydrochloride (10 mg/kg), and maintenance doses of ketamine (2.5–5 mg/kg) were administered as needed. To determine lower esophageal sphincter (LES) position, esophageal pressure was measured by a repeated-station pull-through technique, 1–2 mm at a time, with a multilumen catheter having three proximal openings 3 cm apart. A distal perfused Dentsleeve was used to monitor sphincter pressure after the location of the high-pressure zone was established with the perfused side openings, and the three proximal openings measured the amplitude of contraction in the esophageal body. With the sleeve placed across the LES, the most proximal opening, which was 9 cm proximal to the LES, was used to perfuse 0.1 N HCl. The animals were kept on a slant board at a 15° angle during the perfusion to avoid aspiration. Before acid perfusion, the cat received 0.02 mg/kg atropine to prevent excessive secretion and 1.0 mg/kg im xylazine for anesthesia. After a 5- to 10-min period to allow the additional anesthetic to take effect, 0.1 N HCl was perfused into the esophagus at a rate of 1 ml/min for 30–45 min. After perfusion, the cat was injected subcutaneously with 100 ml saline to prevent dehydration and received 0.01 mg/kg buprenorphine subcutaneously to maintain analgesia. After the animals were returned to their cages, they were monitored for signs of discomfort and maintained on broth and a soft diet. The animals appeared alert and comfortable and ate normally.

In each experiment, two groups of animals were examined: the first group consisted of normal, untreated animals, whereas the second group (animals with esophagitis), after initial measurement of LES pressure, had their esophagi perfused with 0.1 N HCl over three consecutive days, and each esophagus was tested on the fourth day. This protocol has been shown to produce inflammatory changes in the esophageal mucosa and concurrent reduction in the LES in vivo resting pressure and in vitro spontaneous tone, whereas esophageal perfusion with distilled water had no effect on mucosal appearance or LES resting pressure (3, 25).

In a group of six animals, esophageal pressures were measured at 3 cm proximal to the LES during six successive swallows induced by introduction of 2 ml of water in the proximal esophagus. The pressure measurements were obtained on day 1, before beginning the acid perfusion, and on day 4, before the animals were killed.

Preparation of esophageal circular smooth muscle strips and tissue squares. Animals were initially anesthetized with ketamine (Aveco, Fort Dodge, IA), then euthanized with an overdose of phenobarbital (Schering, Kennilworth, NJ). The chest and abdomen were opened with a midline incision exposing the esophagus and stomach. The esophagus and LES were isolated and excised as previously described (6, 7). The esophagus and stomach were removed together and pinned onto a wax block at their in vivo dimensions and orientation. The esophagus and stomach were opened along the lesser curvature. The high-pressure zone is characterized by a visible thickening of the circular muscle layer in correspondence with the squamocolumnar junction and immediately proximal to the sling fibers of the stomach. We have shown previously that a 5- to 8-mm band of tissue, coinciding with the thickened area, constitutes the LES and has distinct characteristics when examined in vivo, in the organ bath. The mucosa and submucosal connective tissue were removed by sharp dissection, and the esophagus was excised, beginning at 1 cm proximal to the thickened area and extending proximally to the smooth-striated muscle junction, which was visible to the naked eye. The 2-mm circular muscle strips were mounted in separate 1-ml muscle chambers and equilibrated for 1 h with continuous perfusion of oxygenated physiological salt solution (PSS) as previously described in detail (5, 6, 10).

To prepare esophageal muscle for Western blot and enzyme immunoassay, the circular muscle layer was cut into 0.5-mm-thick slices with a Stadie Riggs tissue slicer (Thomas Scientific Apparatus, Philadelphia, PA), and tissue squares were made by cutting twice with a 2-mm blade block, the second cut at a right angle to the first.

Measurements of contraction. The 2-mm-wide circular muscle strips were mounted in separate 1-ml muscle chambers as previously described in detail (4). They were initially stretched to 2.5 g to bring them near conditions of optimum force development and were equilibrated for 2 h while being perfused continuously with oxygenated PSS at 37°C. The PSS contained (in mM) 116.6 NaCl, 21.9 NaHCO3, 1.2 KH2PO4, 3.4 KCl, 2.5 CaCl2, 5.4 glucose, and 1.2 MgCl2. The solution was equilibrated with a gas mixture containing 95% O2 and 5% CO2 at 37°C, pH 7.4.

After equilibration, esophageal strips were stimulated with square-wave pulses of supramaximal voltage, 0.2 ms, 2–10 Hz, 10-s trains, delivered by a stimulator (Grass Instruments model S48) through platinum-wire electrodes placed longitudinally on either side of the strip. After electrical stimulation ended, the strips were equilibrated for 30 min, then cumulative dose responses were obtained for ACh (10–7–10–4 M).

To study the effect of selected cytokines on contraction in response to electrical field stimulation (EFS) and ACh, the strips were then incubated in an appropriate concentration of the cytokine for 2 h, and then contraction in response to EFS and ACh were obtained.

Western blot. Esophageal and LES circular muscle (100 mg) obtained from thin circular muscle slices, as described in Preparation of esophageal circular smooth muscle tissue squares, was homogenized in 2 ml PBS (Sigma, St. Louis, MO) (pH 7.4) containing (in M) 0.01 phosphate buffer, 0.0027 KCl, and 0.137 NaCl. The suspension was centrifuged at 12,000 g for 20 min. The supernatant was frozen in liquid nitrogen for later use. The supernatant was mixed with SDS loading buffer (Sigma) containing 0.125 M Tris·HCl (pH 6.8), 20% glycerol, 10% 2 mercaptoethanol, 0.004% bromophenol blue, and 4% SDS and was boiled for 5 min. Prestained molecular weight marker was prepared in the same manner. After being boiled, these supernatant samples were subjected to SDS-PAGE (90 V, 2 h) using 15% SDS gel. The separated proteins were electrophoretically transferred to a nitrocellulose membrane (Bio-Rad, Melville, NY) at 100 V for 1 h. Transfer of proteins to the nitrocellulose membrane was confirmed with ponceau S staining reagent (Sigma). To block nonspecific binding, the nitrocellulose membrane was incubated in 5% donkey serum in PBS for 2 h followed by three rinses in serum-free buffer. Samples were incubated with anti-IL-1{beta} (1:500, 2 h; R&D Systems, Minneapolis MN), anti-IL-6 (1:1,000, overnight; R&D Systems), or anti-TNF-{alpha} (1:150, overnight; Santa Cruz Biotechnology, Santa Cruz, CA) with shaking followed by three washes with antibody-free PBS with 0.5% Tween 20. This was followed by a 60-min incubation in peroxidase-conjugated donkey anti-goat IgG antibody (1:5,000) (Jackson Immunoresearch, West Grove, PA). Detection was achieved with an enhanced chemiluminescence agent (Amersham, Arlington Heights, IL). Molecular weight was estimated by comparison of sample bands with prestained molecular weight marker (Amersham).

Measurement of IL-{beta}, IL-6, and TNF-{alpha}. Esophageal and LES circular muscle (100 mg) was homogenized in 2 ml PBS (pH 7.4). Homogenization consisted of three 10- to 20-s bursts with a Tissue Tearer (Biospec). The suspension was centrifuged at 2,000 g, 4°C, for 20 min. An aliquot of homogenate was taken for protein determination. The supernatant was frozen in liquid nitrogen for later use. The tissue concentrations of cytokines were measured by using enzyme immunoassay kits from Cayman Chemical (Ann Arbor, MI) for IL-6 and TNF-{alpha} and from R&D Systems for IL-1{beta}.

ACh release. The release of ACh was measured by using a well-established technique in which ACh stores in a circular smooth muscle preparation are previously labeled with [3H]choline. (14). This technique has been used extensively to examine myenteric or submucosal plexus function of several species (33, 54, 55). Muscle strips were mounted in 1-ml muscle chambers as previously described (4, 5). Mounted strips were incubated for 1 h at 37°C in Krebs buffer containing 0.2 µM [3H]choline (80 Ci/mM; New England Nuclear, Boston, MA), 50 µM physostigmine, and 10 µM hemicholinium. The strips were washed by changing the solution every 3 min for 1 h. After 1 h, the basal tritium release approached a plateau level. After incubation in [3H]choline, the strips were washed three times with 1 ml Krebs containing 50 µM physostigmine and 10 µM hemicholinium alone, and the 3-ml sample was collected and used as basal release. To measure EFS-induced ACh release, strips were stimulated with the appropriate frequency for 0.2 ms. After 30 s, strips were washed three times with 1 ml Krebs containing and 50 µM physostigmine and 10 µM hemicholinium alone, and the 3-ml sample was collected for radioactivity measurement. Strips were allowed to rest 30 min before the next stimulation. Frequencies tested included 0.5, 1, 2, and 5 Hz. Under these experimental conditions, Collins (14) reported that 90% of the radioactivity in the superfusate was [3H]ACh as measured by HPLC.

Protein determination. The amount of protein present was determined by colorimetric assay (Bio-Rad) according to the method of Bradford (8).

Materials. The agents used were SDS from Bio-Rad (Hercules, CA), polyacrylamide from BDH Chemicals (Poole, England), acetic acid from Malinkrokt Specialty Chemicals (Paris, KY), IL-6 and TNF-{alpha} from Pierce Endogen (Rockford, IL), TNF-{alpha} antibody from Santa Cruz Biotechnology, and IL-6 antibody and IL-{beta} antibody from R&D Systems. ACh, physostigmine, hemicholinium, saponin, and other reagents were purchased from Sigma.

Statistical analysis. Data are expressed as means ± SE. Statistical differences between means were determined by Student's t-test. Differences between multiple groups were tested by using ANOVA for repeated measures and checked for significance using Scheffé's F-test.


    RESULTS
 TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
In normal animals, the in vivo amplitude of esophageal peristaltic contraction during induced swallowing averaged 107 ± 6 mmHg. After repeated esophageal perfusion with HCl, the contraction was significantly decreased (4 ± 1 mmHg), reflecting reduced contraction of the circular muscle (P < 0.01, unpaired t-test). To investigate the mechanisms responsible for this decrease in pressure, circular muscle strips from normal and acid-perfused esophagi were tested in vitro.

Figure 1 shows that esophageal circular muscle contraction in response to EFS is largely mediated by ACh, as previously reported (2), because the contraction is almost abolished by atropine. Figure 2 shows frequency-response curves for normal and esophagitis circular muscle strips. For normal specimens, the amplitude of contraction in response to electrical (i.e., neural) stimulation was greatest at 5 Hz and was 5.0 ± 1.3 g. EFS-induced contraction was significantly reduced (1.2 ± 0.6 g; n = 3, P < 0.05 by ANOVA) after acute esophagitis. In contrast, ACh-induced contraction was not significantly affected, suggesting that esophageal circular muscle is not damaged by acid perfusion but that the release of excitatory neurotransmitters may be affected. The maximum contraction was 4.0 ± 0.8 and 4.7 ± 0.5 g for control and esophagitis strips, respectively.



View larger version (10K):
[in this window]
[in a new window]
 
Fig. 1. Frequency-response curves (2 ms, 10-s trains, frequency as shown) for control and atropine-treated circular muscle strips. Amplitude of contraction in response to electrical (i.e., neural) stimulation was almost abolished by atropine (P < 0.05, ANOVA) indicating that electrical field stimulation (EFS)-induced contraction is mediated by release of ACh. Values are means ± SE.

 


View larger version (15K):
[in this window]
[in a new window]
 
Fig. 2. Frequency-response curves for normal and esophagitis circular muscle strips. Amplitude of contraction in response to electrical (i.e., neural) stimulation was significantly reduced (1.2 ± 0.6 g) after acute esophagitis (AE) compared with normal specimens (5.0 ± 1.3 g; P < 0.05 by ANOVA). In contrast, ACh-induced contraction was not significantly affected, suggesting that esophageal circular muscle is not damaged by acid perfusion but that the release of excitatory neurotransmitters may be affected. Values are means ± SE.

 
To confirm esophagitis-induced impairment of ACh release, we measured ACh release in response to EFS at frequencies of 5 Hz, which produced maximal contraction or lower (Fig. 3). 3[H]ACh release, measured in the supernatant, increased with frequency of EFS compared with levels in the absence of EFS (basal). The measurements confirmed that EFS-induced release of ACh was significantly reduced (P < 0.01, ANOVA) in muscle strips from esophagitis animals, resulting in 258 ± 17 counts/min (cpm)/g of tissue at 5 Hz compared with normal controls (621 ± 42 cpm/g tissue at 5 Hz).



View larger version (14K):
[in this window]
[in a new window]
 
Fig. 3. The release of ACh was measured by using a well-established technique in which ACh stores in a circular smooth muscle preparation were previously labeled with 3[H]choline (14). 3[H]ACh release, measured in the supernatant, increased with frequency of EFS compared with levels in the absence of EFS (basal). EFS-induced release of ACh was significantly reduced (P < 0.01, ANOVA) in muscle strips from esophagitis animals, resulting in 258 ± 17 counts/min (cpm)/g tissue at 5 Hz compared with 621 ± 42 cpm/g tissue at 5 Hz in normal controls. Values are means ± SE.

 
IL-1{beta}-induced changes. To examine whether IL-1{beta} may contribute to changes in motor function associated with experimental esophagitis, we incubated normal circular muscle strips in IL-1{beta} (100 U/ml) for 2 h and examined IL-1{beta}-induced changes in contraction in response to EFS or ACh. Figure 4 shows frequency-response curves for normal controls and IL-1{beta}-incubated circular muscle strips. The amplitude of contraction in response to electrical (i.e., neural) stimulation was significantly reduced (89 ± 7%; n = 5, P < 0.001 by ANOVA) after IL-1{beta} treatment. At 5 Hz, contraction was 4.3 ± 1.0 g for normal and 1.5 ± 0.9 g for IL-1{beta}-treated strips. In contrast, ACh-induced contraction was not significantly affected, suggesting that esophageal circular muscle is not affected by IL-1{beta} but that the release of excitatory neurotransmitters may be inhibited.



View larger version (17K):
[in this window]
[in a new window]
 
Fig. 4. Frequency-response curves for normal control and IL-1{beta}-incubated circular muscle strips (100 U/ml, 2 h). Amplitude of contraction in response to stimulation was significantly reduced (89 ± 7%) after acute IL-1{beta} treatment compared with normal specimens (P < 0.001, ANOVA). In contrast, ACh-induced contraction was not significantly affected, suggesting that esophageal circular muscle is not affected by IL-1{beta} but that the release of excitatory neurotransmitters may be inhibited. Values are means ± SE for 5 cats.

 
We therefore measured ACh release in response to EFS (Fig. 5) from circular muscle incubated in IL-1{beta} (100 U/ml, 2 h). 3[H]ACh release, measured in the supernatant, was significantly reduced (P < 0.01, ANOVA) in IL-1{beta}-treated muscle strips, resulting in 316 ± 36 cpm/g tissue at 5 Hz compared with normal controls (621 ± 42 cpm/g tissue at 5 Hz).



View larger version (14K):
[in this window]
[in a new window]
 
Fig. 5. ACh release in response to EFS from circular muscle incubated in IL-1{beta} (100 U/ml, 2 h). 3[H]ACh release, measured in the supernatant, was significantly reduced (P < 0.01, ANOVA) in IL-1{beta}-treated muscle strips, resulting in 316 ± 36 cpm/g tissue at 5 Hz compared with 621 ± 42 cpm/g tissue at 5 Hz in normal controls. Values are means ± SE.

 
To determine whether IL-1{beta} is elevated in experimental esophagitis, the presence of IL-1{beta} in the circular muscle layer was examined. Circular muscle tissue was prepared by slicing the circular muscle layer with a Stadie-Riggs slicer, as described in METHODS. The slices consisted largely (~90%) of circular muscle, although the presence of other cell types cannot be excluded. Rat IL-1{beta} antibody was used to detect IL-1{beta} levels by Western blot in the muscle. Figure 6 shows that IL-1{beta} levels increased after experimental esophagitis. These data were confirmed by measurement of esophageal smooth muscle IL-1{beta} by enzyme immunoassay. The figure shows that IL-1{beta} levels increased from 853 ± 99 pg/mg protein in normal esophagus to 2,017 ± 672 pg/mg protein after induction of esophagitis. These data suggest that inflammation-induced motor dysfunction in esophagitis may result from elevated levels of IL-1{beta}, which reduces the release of the endogenous excitatory neurotransmitter ACh.



View larger version (23K):
[in this window]
[in a new window]
 
Fig. 6. IL-1{beta} levels in esophageal circular smooth muscle are elevated in acute experimental esophagitis. Rat IL-1{beta} antibody was used to detect IL-1{beta} levels by Western blot in cat circular esophageal smooth muscle. IL-1{beta} levels significantly increased (P < 0.001, unpaired t-test) after experimental esophagitis. Similarly, IL-{beta} levels, measured by enzyme immunoassay, were higher after induction of esophagitis compared with control esophageal smooth muscle. Values are means ± SE for 3 cats.

 
IL-6-induced changes. Similarly, we examined IL-6-induced changes in contraction in response to EFS or ACh. Figure 7 shows frequency-response curves for normal controls and IL-6-incubated (1 ng/ml for 1 h) circular muscle strips. The amplitude of contraction in response to electrical (i.e., neural) stimulation was significantly reduced (58 ± 10%; n = 6 for control, P < 0.05 by ANOVA) after IL-6 treatment. At 5 Hz, contraction was 8.9 ± 2.08 g for normal and 2.4 ± 1.0 g for IL-6-treated strips. In contrast, ACh-induced contraction was not significantly affected (control, n = 7; IL-6, n = 8), suggesting that, similarly to IL-1{beta}, esophageal circular muscle is not affected by IL-6 but that the release of excitatory neurotransmitters may be inhibited.



View larger version (18K):
[in this window]
[in a new window]
 
Fig. 7. Frequency-response curves for normal controls and IL-6-incubated (1 ng/ml, 1 h) circular muscle strips. The amplitude of contraction in response to EFS was significantly reduced (58 ± 10%; P < 0.05 by ANOVA) after IL-6 treatment. ACh-induced contraction was not significantly affected, suggesting that, similarly to IL-1{beta}, esophageal circular muscle is not affected by IL-6 but that the release of excitatory neurotransmitters may be inhibited. Values are means ± SE for 6–8 cats.

 
We therefore measured ACh release in response to EFS (Fig. 8) from circular muscle incubated in IL-6 (1 ng/ml, 2 h). 3[H]ACh release, measured in the supernatant, was significantly reduced (P < 0.01, ANOVA) in IL-6-treated muscle strips, resulting in 218 ± 23 cpm/g tissue at 5 Hz compared with normal controls (621 ± 42 cpm/g tissue at 5 Hz).



View larger version (13K):
[in this window]
[in a new window]
 
Fig. 8. ACh release in response to EFS from circular muscle incubated in IL-6 (1 ng/ml, 2 h). 3[H]ACh release, measured in the supernatant, was significantly reduced (P < 0.01, ANOVA) in IL-6-treated muscle strips, resulting in 218 ± 23 cpm/g tissue at 5 Hz, compared with 621 ± 42 cpm/g tissue at 5 Hz in normal controls. Values are means ± SE.

 
To determine whether IL-6 is elevated in experimental esophagitis, the presence of IL-6 in the circular smooth muscle layer was examined by Western blot and enzyme immunoassay. Figure 9 shows that IL-6 levels in esophageal circular smooth muscle significantly increased after induction of experimental esophagitis as measured by enzyme immunoassay (P < 0.05, unpaired t-test). IL-6 levels in esophageal circular smooth muscle increased from 241 ± 72 to 659 ± 84 pg/mg protein after induction of experimental esophagitis. Western blot data did not reach statistical significance because of the large standard errors in the assay. The trend, however, was in the right direction and in agreement with the difference in IL-6 content as measured by immunoassay.



View larger version (24K):
[in this window]
[in a new window]
 
Fig. 9. IL-6 levels in esophageal circular smooth muscle are elevated in acute experimental esophagitis. IL-6 in the circular muscle smooth layer of the esophagus was examined by Western blot and by enzyme immunoassay. IL-6 levels in esophageal circular smooth muscle significantly increased after experimental esophagitis as measured by enzyme immunoassay (P < 0.05, unpaired t-test). Western blot did not reach statistical significance. Values are means ± SE.

 
These data suggest that, similarly to IL-1{beta}, IL-6 may contribute to inflammation-induced motor dysfunction in esophagitis. Elevated levels of IL-6 may contribute to reduced release of the endogenous excitatory neurotransmitter ACh in response to electrical (i.e., neural) stimulation, contributing to a reduction in neurally mediated contraction.

TNF-{alpha}. In contrast to IL-1{beta} and IL-6, TNF-{alpha} (1 ng/ml, 1 h) did not significantly affect either EFS- or ACh-induced contraction of esophageal circular muscle strips (Fig. 10). At a high concentration (100 ng/ml, 1 h), TNF-{alpha} significantly reduced both EFS- and ACh-induced contraction, possibly by directly affecting myogenic contractile mechanisms (Fig. 11).



View larger version (16K):
[in this window]
[in a new window]
 
Fig. 10. Frequency-response curves for normal controls and TNF-{alpha}-incubated (1 ng/ml, 1 h) circular muscle strips. TNF-{alpha} did not significantly affect either EFS- or ACh-induced contraction of esophageal circular muscle strips. Values are means ± SE.

 


View larger version (15K):
[in this window]
[in a new window]
 
Fig. 11. Frequency-response curves for normal controls and TNF-{alpha}-incubated (100 ng/ml, 1 h) circular muscle strips At a high concentration, TNF-{alpha} reduced both EFS- and ACh-induced contraction, possibly by directly affecting myogenic contractile mechanisms. Values are means ± SE.

 
To determine whether these effects of TNF-{alpha} on esophageal circular muscle were pharmacological or physiological, we examined, by Western blot and enzyme immunoassay, whether TNF-{alpha} was present in the circular muscle layer and increased with experimental esophagitis. Figure 12 shows that TNF-{alpha} levels were barely detectable in normal muscle and did not increase after experimental esophagitis. TNF-{alpha} levels were also measured by immunoassay, as shown in the figure. TNF-{alpha} levels in esophageal circular smooth muscle were low and did not increase after the induction of experimental esophagitis.



View larger version (20K):
[in this window]
[in a new window]
 
Fig. 12. TNF-{alpha} in the circular muscle smooth layer of the esophagus was examined by Western blot and by enzyme immunoassay. TNF-{alpha} levels were barely detectable in normal muscle (lanes 2–4) and did not increase after experimental esophagitis (lanes 6–7). Lane 1 shows a positive control for TNF-{alpha}. Data shown are from 3 normal cats and 3 esophagitis cats, with each lane representing a different cat. As measured by immunoassay, TNF-{alpha} levels in esophageal circular smooth muscle did not change after induction of experimental esophagitis. Immunoassay values are means ± SE for 3 cats.

 

    DISCUSSION
 TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
The role of cytokines as key mediators of inflammation is firmly established, and their blockade has led to the development of new forms of therapy for IBD (24, 41, 50, 51). IBD in animals or humans is associated with changes in motility that may reflect alterations in the function of enteric nerve and muscle (39), as demonstrated both in vivo and in vitro (57). Several animal models of intestinal inflammation have been developed, and abnormalities of intestinal motility can be detected in animals with chemically induced colitis. They include colitis induced by agents administered either directly by enema, such as acetic acid, formalin, or trinitrobenzene sulfonic acid, or by mouth, such as carrageenan or dextran sulfate sodium. In addition, a model of parasite-induced colitis, such as Trichinella spiralis (14, 15) has been well characterized. Experimental evidence increasingly suggests that IBD results from dysfunctional immunoregulation manifested by an inappropriate production of mucosal cytokines (29).

In this cat model of experimental esophagitis, we show that esophageal motor function is impaired both in vivo and in vitro. After induction of experimental esophagitis, the in vivo amplitude of the pressure excursion recorded during swallowing was drastically reduced compared with normal animals. Similarly, in vitro contraction of circular muscle strips in response to EFS, which is neurally mediated, was significantly reduced in animals with esophagitis. In contrast, contraction in response to the neurotransmitter ACh, which directly activates muscarinic receptors on the muscle cell membrane, was not affected, suggesting that muscle function is not directly affected by esophagitis-related inflammation. In contrast, the neurons mediating esophageal contraction may be affected by inflammation, and the observed inflammation-induced changes may reflect reduced release of the endogenous neurotransmitter ACh. This conclusion is supported by reduced in vitro release of ACh in response to electrical (i.e., neural) stimulation in experimental esophagitis.

Cytokines and intestinal inflammation. As previously mentioned, IL-1{beta}, IL-6, and TNF-{alpha} are the major proinflammatory cytokines involved in the inflammatory cascade. Enhanced production of IL-1 has been demonstrated in animal models of intestinal inflammation (16, 40), in the colonic mucosa from ulcerative colitis patients (20, 28, 35), and in monocytes isolated from colonic mucosa of ulcerative colitis patients (38). Tissue levels of IL-1{beta} correlate with disease activity, and the ratio of the endogenous IL-1 receptor antagonist IL-1ra to IL-1 shows the closest correlation with inflammation (12, 44). Administration of IL-1ra attenuates rabbit immune complex colitis (17), and reduction of IL-1ra levels by either gene knockout in mice (26) or by antibody neutralization in rabbits (19) increases the susceptibility to the induction of experimental colitis. These data support an important role of IL-1{beta} in the pathogenesis of gut inflammation.

IL-6, a broad-spectrum cytokine with characteristics of an acute-phase reactant, is produced by immune cells, intestinal epithelial cells, and smooth muscle cells, and IL-6 production is profoundly stimulated by treatment with IL-1{beta} (42). Circulating levels of IL-6 are high in patients with active Crohn's disease (37) and are consistently elevated in IBD tissues, where its source is primarily macrophages and epithelial cells (34). TNF-{alpha} is another pleiotropic cytokine with multiple and potent proinflammatory activity (45), and its blockade results in profound downregulatory effects on intestinal inflammation, particularly in Crohn's disease (1). We therefore investigated a possible role of these proinflammatory cytokines in esophagitis-induced motor dysfunction.

Cytokines and esophageal motor dysfunction. Only a handful of reports have examined cytokine content in esophagitis mucosa or muscle. Recently, immunological determinants of esophageal response to gastroesophageal reflux have been examined to demonstrate that, in esophagitis, endoscopic and histopathological grades of inflammation correlate with mRNA expression of IL-1{beta}, the chemokine IL-8, and IFN-{gamma}. These cytokines are increased 3- to 10-fold compared with noninflamed squamous or Barrett's esophageal samples (21). IL-6 release by tissue fragments obtained from esophageal biopsies was determined in children with reflux esophagitis. Esophageal cells from biopsy tissue fragments synthesize and release in vitro a significantly higher amount of IL-6 than controls (18).

We found that the changes in muscle contraction induced by esophagitis were reproduced in vitro by incubating esophageal circular muscle strips in IL-1{beta} or IL-6. Incubation of normal circular muscle strips in IL-1{beta} or IL-6 resulted in reduced in vitro response to EFS but did not significantly affect the response to direct myogenic stimulation with ACh. Similarly to experimental esophagitis, the in vitro release of ACh in response to EFS was significantly reduced by either IL-1{beta} or IL-6. In addition, IL-1{beta} and IL-6 levels were elevated in the circular smooth muscle layer after the induction of experimental esophagitis, supporting the proposition that an esophagitis-induced increase in the levels of these cytokines in the esophageal circular muscle layer may contribute to the reduction of in vivo response to swallowing and in vitro response to EFS. Exogenous IL-6 caused similar effects to those of IL-1{beta} and acid-induced esophagitis. IL-6 may be produced by macrophages and epithelial cells, and its production can be stimulated by IL-{beta}. Collin and colleagues (31, 49, 56) have used cultured smooth muscle cells to show that IL-1{beta} can stimulate IL-6 synthesis by muscle cells . Thus the effect of IL-1{beta} could reflect, in part, stimulation of IL-6 production.

In contrast, TNF-{alpha} did not reproduce esophagitis-induced motor changes. At low pharmacological doses (1 ng/ml), TNF-{alpha} failed to affect contraction in response to either ACh or EFS, and at high doses (100 ng/ml), it reduced both. Finally, TNF-{alpha} levels were barely detectable in normal tissue and did not increase in esophagitis.

These data are consistent with recently reported findings in human esophagitis (48). Endoscopic mucosal biopsies obtained from the esophagus of adult patients with endoscopic evidence of esophagitis were organ-cultured overnight in a Transwell system, and the undernatant was recovered for cytokine content. IL-6 and IL-8 were present in all biopsies, and patients with reflux esophagitis showed increased concentration of the proinflammatory cytokine IL-6 in the inflamed tissue compared with controls. IL-1{beta} was detected in patients with more severe inflammation, whereas TNF-{alpha} was present sporadically and in low concentrations (48). These data support the view that inflammation-induced motor dysfunction in esophagitis results from elevated levels of IL-1{beta} and IL-6, which reduce the release of the endogenous excitatory neurotransmitter ACh.

Increased release of substance P by the intestine in response to inflammation or to inflammatory cytokines has been previously reported (23, 30, 32). EFS-induced circular muscle contraction, however, is largely mediated by ACh, because contraction is almost abolished by atropine. We did not examine changes in release of other neurotransmitters, because diminished release of ACh is sufficient to account for the observed changes in esophagitis specimens.

These inflammation-induced changes are similar to those reported by Collins and colleagues (14, 15, 22) in T. spiralis-infected rodents. T. spiralis infection induced an acute inflammatory response in intestinal muscle of rats and mice, resulting in suppression of neurotransmitter release, such as ACh and norepinephrine, by enteric nerves. The proinflammatory cytokines IL-1{beta} and TNF-{alpha} released from macrophages were reported as potential mediators of the functional alterations because 1) administration of exogenous IL-1{beta} and TNF-{alpha} to normal control tissue mimicked the impairment of neurotransmitter release from longitudinal muscle-myenteric plexus observed during T. spiralis infection, 2) increased mRNA expression of these cytokines was present in the longitudinal muscle-myenteric plexus of infected animals, and 3) macrophage depletion prevented the suppression in 3[H]ACh release (22, 27, 39).

Unlike this well-explored model of inflammation, and in agreement with human esophagitis (48), our esophagitis cat model does not involve TNF-{alpha} but only IL-1{beta} and IL-6. Recent preliminary data (13) suggest that, when exposed to acid, esophageal mucosa produces both IL-1{beta} and IL-6, but only IL-6 is released to diffuse to the muscle layer, where it induces production of H2O2. H2O2, in turn, may induce production of IL-1{beta} and other inflammatory mediators both in the muscle and mucosal layers. Thus, although initially the mucosal layer releases only IL-6, prolonged inflammation may result in the presence of IL-1{beta} and other inflammatory mediators, both in the mucosa and muscle layer.

In summary, we conclude that proinflammatory cytokines play an important pathophysiological role in experimental esophagitis in the cat and that IL-1{beta} and IL-6, but not TNF-{alpha}, are present in the circular muscle layer and may contribute to reduced esophageal contraction in this model by inhibiting release of ACh from myenteric neurons.


    GRANTS
 TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
This work was supported by National Institute of Diabetes and Digestive and Kidney Diseases Grants RO1-DK-57030 and DK-50984-06.


    FOOTNOTES
 

Address for reprint requests and other correspondence: K. M. Harnett, G.I. Motility Research Lab., SWP5 Rhode Island Hospital and Brown Univ., 593 Eddy St., Providence RI 02903 (E-mail: karen_harnett{at}brown.edu)

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.


    REFERENCES
 TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 

  1. Baert FJ, D'Haens GR, Peeters M, Hiele MI, Schaible TF, Shealy D, Geboes K, and Rutgeerts PJ. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology 116: 22–28, 1999.[ISI][Medline]
  2. Behar J, Guenard V, Walsh JH, and Biancani P. Vasoactive intestinal peptide and acetylcholine: neurotransmitters of cat esophagus. Am J Physiol Gastrointest Liver Physiol 257: G380–G385, 1989.[Abstract/Free Full Text]
  3. Biancani P, Barwick K, Selling J, and McCallum R. Effects of acute experimental esophagitis in mechanical properties of the lower esophageal sphincter. Gastroenterology 87: 8–16, 1984.[ISI][Medline]
  4. Biancani P, Billett G, Hillemeier C, Nissenshon M, Rhim BY, Sweczack S, and Behar J. Acute experimental esophagitis impairs signal transduction in cat LES circular muscle. Gastroenterology 103: 1199–1206, 1992.[ISI][Medline]
  5. Biancani P, Harnett KM, Sohn UD, Rhim BY, Behar J, Hillemeier C, and Bitar KN. Differential signal transduction pathways in cat lower esophageal sphincter tone and response to ACh. Am J Physiol Gastrointest Liver Physiol 266: G767–G774, 1994.[Abstract/Free Full Text]
  6. Biancani P, Hillemeier C, Bitar KN, and Makhlou GM. Contraction mediated by Ca2+ influx in the esophagus and by Ca2+ release in the LES. Am J Physiol Gastrointest Liver Physiol 253: G760–G766, 1987.[Abstract/Free Full Text]
  7. Biancani P, Zabinski M, Kerstein M, and Behar J. Lower esophageal sphincter mechanics: anatomic and physiologic relationships of the esophagogastric junction of the cat. Gastroenterology 82: 468–475, 1982.[ISI][Medline]
  8. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248–254, 1976.[CrossRef][ISI][Medline]
  9. Braegger CP, Nicholls S, Murch SH, Stephens S, and MacDonald TT. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 339: 89–91, 1992.[CrossRef][ISI][Medline]
  10. Cao WB, Harnett KM, Chen Q, Jain MK, Behar J, and Biancani P. Group I secreted PLA2 and arachidonic acid metabolites in the maintenance of cat LES tone. Am J Physiol Gastrointest Liver Physiol 277: G585–G598, 1999.[Abstract/Free Full Text]
  11. Cappello M, Keshav S, Prince C, Jewell DP, and Gordon S. Detection of mRNAs for macrophage products in inflammatory bowel disease by in situ hybridisation. Gut 33: 1214–1219, 1992.[Abstract]
  12. Casini-Raggi V, Kam L, Chong YJ, Fiocchi C, Pizarro TT, and Cominelli F. Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease. A novel mechanism of chronic intestinal inflammation. J Immunol 154: 2434–2440, 1995.[Abstract/Free Full Text]
  13. Cheng L, Harnett KM, Cao W, Behar J, Fiocchi C, and Biancani P. In vitro model of acute esophagitis in the cat (Abstract). Gastroenterology 124: A160, 2003.[CrossRef]
  14. Collins S, Blennerhassett P, Blennerhassett M, and Vermillion D. Impaired acetylcholine release from the myenteric plexus of Trichinella-infected rats. Am J Physiol Gastrointest Liver Physiol 257: G898–G903, 1989.[Abstract/Free Full Text]
  15. Collins S, Blennerhassett P, Vermillion D, Davis K, Langer J, and Ernst P. Impaired acetylcholine release in the inflamed rat intestine is T cell independent. Am J Physiol Gastrointest Liver Physiol 263: G198–G201, 1992.[Abstract/Free Full Text]
  16. Cominelli F, Nast CC, Clark BD, Schindler R, Lierena R, Eysselein VE, Thompson RC, and Dinarello CA. Interleukin 1 (IL-1) gene expression, synthesis, and effect of specific IL-1 receptor blockade in rabbit immune complex colitis. J Clin Invest 86: 972–980, 1990.[ISI][Medline]
  17. Cominelli F, Nast CC, Duchini A, and Lee M. Recombinant interleukin-1 receptor antagonist blocks the proinflammatory activity of endogenous interleukin-1 in rabbit immune colitis. Gastroenterology 103: 65–71, 1992.[ISI][Medline]
  18. Corrado G, Zicari A, Cavaliere M, Rea P, Pacchiarotti C, Cerroni F, Pontieri G, and Cardi E. Increased release of interleukin-6 by oesophageal mucosa in children with reflux oesophagitis. Eur J Gastroenterol Hepatol 11: 839–843, 1999.[ISI][Medline]
  19. Ferretti M, Casini-Raggi V, Pizarro TT, Eisenberg SP, Nast CC, and Cominelli F. Neutralization of endogenous IL-1 receptor antagonist exacerbates and prolongs inflammation in rabbit immune colitis. J Clin Invest 94: 449–453, 1994.[ISI][Medline]
  20. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 115: 182–205, 1998.[ISI][Medline]
  21. Fitzgerald RC, Onwuegbusi BA, Bajaj-Elliott M, Saeed IT, Burnham WR, and Farthing MJ. Diversity in the oesophageal phenotypic response to gastro-oesophageal reflux: immunological determinants. Gut 50: 451–459, 2002.[Abstract/Free Full Text]
  22. Galeazzi F, Haapala EM, van Rooijen N, Vallance BA, and Collins SM. Inflammation-induced impairment of enteric nerve function in nematode-infected mice is macrophage dependent. Am J Physiol Gastrointest Liver Physiol 278: G259–G265, 2000.[Abstract/Free Full Text]
  23. Grider JR. Interleukin-1 beta selectively increases substance P release and augments the ascending phase of the peristaltic reflex. Neurogastroenterol Motil 15: 607–615, 2003.[CrossRef][ISI][Medline]
  24. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, and Rutgeerts P. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359: 1541–1549, 2002.[CrossRef][ISI][Medline]
  25. Higgs RH, Castell DO, and Eastwood GL. Studies on the mechanism of esophagitis-induced lower esophageal sphincter hypotension in cats. Gastroenterology 71: 51–56, 1976.[ISI][Medline]
  26. Hirsch E, Irikura VM, Paul SM, and Hirsh D. Functions of interleukin 1 receptor antagonist in gene knockout and overproducing mice. Proc Natl Acad Sci USA 93: 11008–11013, 1996.[Abstract/Free Full Text]
  27. Hurst SM and Collins SM. Mechanism underlying tumor necrosis factor-alpha suppression of norepinephrine release from rat myenteric plexus. Am J Physiol Gastrointest Liver Physiol 266: G1123–G1129, 1994.[Abstract/Free Full Text]
  28. Ishiguro Y. Mucosal proinflammatory cytokine production correlates with endoscopic activity of ulcerative colitis. J Gastroenterol 34: 66–74, 1999.[CrossRef][ISI][Medline]
  29. Kanazawa S, Tsunoda T, Onuma E, Majima T, Kagiyama M, and Kikuchi K. VEGF, basic-FGF, and TGF-beta in Crohn's disease and ulcerative colitis: a novel mechanism of chronic intestinal inflammation. Am J Gastroenterol 96: 822–828, 2001.[CrossRef][ISI][Medline]
  30. Khan I and al-Awadi FM. Colonic muscle enhances the production of interleukin-1 beta messenger RNA in experimental colitis. Gut 40: 307–312, 1997.[Abstract]
  31. Khan I, Blennerhassett MG, Kataeva GV, and Collins SM. Interleukin 1 beta induces the expression of interleukin 6 in rat intestinal smooth muscle cells. Gastroenterology 108: 1720–1728, 1995.[ISI][Medline]
  32. Khan I and Collins SM. Fourth isoform of preprotachykinin messenger RNA encoding for substance P in the rat intestine. Biochem Biophys Res Commun 202: 796–802, 1994.[CrossRef][ISI][Medline]
  33. Kilbinger H and Wessler I. Inhibition by acetylcholine of the stimulation-evoked release of [3H]acetylcholine from the guinea-pig myenteric plexus. Neuroscience 5: 1331–1340, 1980.[CrossRef][ISI][Medline]
  34. Kusugami K, Fukatsu A, Tanimoto M, Shinoda M, Haruta J, Kuroiwa A, Ina K, Kanayama K, Ando T, Matsuura T, Yamaguchi T, Morise K, Ieda M, Iokawa H, Ishihara A, and Sarai S. Elevation of interleukin-6 in inflammatory bowel disease is macrophage- and epithelial cell-dependent. Dig Dis Sci 40: 949–959, 1995.[ISI][Medline]
  35. Ligumsky M, Simon PL, Karmeli F, and Rachmilewitz D. Role of interleukin 1 in inflammatory bowel disease–enhanced production during active disease. Gut 31: 686–689, 1990.[Abstract]
  36. Luzza F, Parrello T, Sebkova L, Pensabene L, Imeneo M, Mancuso M, LaVecchia A, Monteleone G, Strosciuglio P, and Pallone F. Expression of proinflammatory and Th1 but not Th2 cytokines is enhanced in gastric mucosa of Helicobacter pylori infected children. Dig Liver Dis 33: 14–20, 2000.[ISI]
  37. Mahida YR, Kurlac L, Gallagher A, and Hawkey CJ. High circulating concentrations of interleukin-6 in active Crohn's disease but not ulcerative colitis. Gut 32: 1531–1534, 1991.[Abstract]
  38. Mahida YR, Wu K, and Jewell DP. Enhanced production of interleukin 1-beta by mononuclear cells isolated from mucosa with active ulcerative colitis of Crohn's disease. Gut 30: 835–838, 1989.[Abstract]
  39. Main C, Blennerhassett P, and Collins SM. Human recombinant interleukin 1 beta suppresses acetylcholine release from rat myenteric plexus. Gastroenterology 104: 1648–1654, 1993.[ISI][Medline]
  40. McCall RD, Haskill S, Zimmermann EM, Lund PK, Thompson RC, and Sartor RB. Tissue interleukin 1 and interleukin-1 receptor antagonist expression in enterocolitis in resistant and susceptible rats. Gastroenterology 106: 960–972, 1994.[ISI][Medline]
  41. Nahar IK, Shojania K, Marra CA, Alamgir AH, and Anis AH. Infliximab treatment of rheumatoid arthritis and Crohn's disease. Ann Pharmacother 37: 1256–1265, 2003.[Abstract/Free Full Text]
  42. Ng EK, Panesar N, Longo WE, Shapiro MJ, Kaminski DL, Tolman KC, and Mazuski JE. Human intestinal epithelial and smooth muscle cells are potent producers of IL-6. Med Inf (Lond) 12: 3–8, 2003.
  43. Nilsen EM, Jahnsen FL, Lundin KE, Johansen FE, Fausa O, Sollid LM, Jahnsen J, Scott H, and Brandtzaeg P. Gluten induces an intestinal cytokine response strongly dominated by interferon gamma in patients with celiac disease. Gastroenterology 115: 551–563, 1998.[ISI][Medline]
  44. Nishiyama T, Mitsuyama K, Toyonaga A, Sasaki E, and Tanikawa K. Colonic mucosal interleukin 1 receptor antagonist in inflammatory bowel disease. Digestion 55: 368–373, 1994.[ISI][Medline]
  45. Papadakis KA and Targan SR. Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology 119: 1148–1157, 2000.[ISI][Medline]
  46. Podolsky D and Fiocchi C. Cytokines, chemokines, growth factors, eicosanoids and other bioactive molecules in IBD. In: Inflammatory Bowel Disease, edited by Kirsner J. Philadelphia: W. B. Saunders, 1999, p. 191–207.
  47. Reinecker HC, Steffen M, Witthoeft T, Pflueger I, Schreiber S, MacDermott RP, and Raedler A. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 94: 174–181, 1993.[ISI][Medline]
  48. Rieder F, Phillips H, West GA, Chak A, Cooper G, Isenberg G, Ray M, Katz J, Wong R, Post A, O'Shea R, Sivak M, Biancani P, and Fiocchi C. Production of the pro-inflammatory cytokines IL-1{beta}, IL-6 and IL-8 in active esophagitis (Abstract). Gastroenterology 122: A420, 2002.
  49. Ruhl A, Hurst S, and Collins SM. Synergism between interleukins 1 beta and 6 on noradrenergic nerves in rat myenteric plexus. Gastroenterology 107: 993–1001, 1994.[ISI][Medline]
  50. Rutgeerts P, Van Deventer S, and Schreiber S. Review article: the expanding role of biological agents in the treatment of inflammatory bowel disease–focus on selective adhesion molecule inhibition. Aliment Pharmacol Ther 17: 1435–1450, 2003.[CrossRef][ISI][Medline]
  51. Sands BE, Tremaine WJ, Sandborn WJ, Rutgeerts PJ, Hanauer SB, Mayer L, Targan SR, and Podolsky DK. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis 7: 83–88, 2001.[ISI][Medline]
  52. Sartor RB. Cytokines in intestinal inflammation: pathophysiological and clinical considerations. Gastroenterology 106: 533–539, 1994.[ISI][Medline]
  53. Stevens C, Walz G, Singaram C, Lipman ML, Zanker B, Muggia A, Antonioli D, Peppercorn MA, and Strom TB. Tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6 expression in inflammatory bowel disease. Dig Dis Sci 37: 818–826, 1992.[ISI][Medline]
  54. Szerb JC. Endogenous acetylcholine release and labelled acetylcholine formation from [3H]choline in the myenteric plexus of the guinea-pig ileum. Can J Physiol Pharmacol 53: 566–574, 1975.[ISI][Medline]
  55. Teitelbaum DH, O'Dorisio TM, Perkins WE, and Gaginella TS. Somatostatin modulation of peptide-induced acetylcholine release in guinea pig ileum. Am J Physiol Gastrointest Liver Physiol 246: G509–G514, 1984.[Abstract/Free Full Text]
  56. Van Assche G, Barbara G, Deng Y, Lovato P, Gauldie J, and Collins SM. Neurotransmitters modulate cytokine-stimulated interleukin 6 secretion in rat intestinal smooth muscle cells. Gastroenterology 116: 346–353, 1999.[ISI][Medline]
  57. Vrees MD, Pricolo VE, Potenti FM, and Cao W. Abnormal motility in patients with ulcerative colitis: the role of inflammatory cytokines. Arch Surg 137: 439–446, 2002.[Abstract/Free Full Text]
  58. Youngman KR, Simon PL, West GA, Cominelli F, Rachmilewitz D, Klein JS, and Fiocchi C. Localization of intestinal interleukin 1 activity and protein and gene expression to lamina propria cells. Gastroenterology 104: 749–758, 1993.[ISI][Medline]